Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Nippon Kayaku’s Humira Biosimilar Adds nr-axSpA Use
Nippon Kayaku said on March 19 that its biosimilar versions of the anti-TNF-α monoclonal antibody Humira (adalimumab) is now approved for an additional indication of non-radiographic axial spondyloarthritis (nr-axSpA) in Japan. The label expansion was granted to Adalimumab BS Subcutaneous…
To read the full story
Related Article
- Nippon Kayaku’s Humira Biosimilar Adds Pediatric UC Use
March 26, 2026
- Nippon Kayaku Files Humira Biosimilar for nr-axSpA
October 1, 2024
- Humira Filed for nr-axSpA in Japan Based on Public Knowledge: AbbVie
September 2, 2024
BUSINESS
- Sanofi Eyes Double-Digit Annual Growth for Japan Vaccine Business: Exec
May 20, 2026
- Takeda Hit with Massive Damages Verdict in US Amitiza Antitrust Case
May 20, 2026
- Top Generic Makers Grow Sales on Higher Output, Shipment Recovery
May 20, 2026
- Tapinarof Cream Logs Positive Data in Infant Atopic Dermatitis: Shionogi
May 20, 2026
- Bayer Files FXIa Inhibitor Asundexian in Japan
May 20, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…